Tim Peterson

507 total citations
16 papers, 292 citations indexed

About

Tim Peterson is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Tim Peterson has authored 16 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Hematology and 4 papers in Molecular Biology. Recurrent topics in Tim Peterson's work include Chronic Lymphocytic Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (5 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). Tim Peterson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (5 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). Tim Peterson collaborates with scholars based in United States, United Kingdom and India. Tim Peterson's co-authors include Alan Melcher, Richard G. Vile, Laura Tang, Scott E. Strome, Michael J. Buege, Andrew Bateman, Tim Kottke, David S. Riddle, Emmanouela Linardakis and Kevin J. Harrington and has published in prestigious journals such as Blood, Cancer and British Journal of Haematology.

In The Last Decade

Tim Peterson

12 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Peterson United States 8 125 114 110 63 58 16 292
Robin Mueller United States 10 68 0.5× 159 1.4× 270 2.5× 60 1.0× 29 0.5× 14 381
Eva‐Maria König Germany 10 49 0.4× 32 0.3× 66 0.6× 40 0.6× 18 0.3× 15 247
N Tsuruoka Japan 11 63 0.5× 35 0.3× 133 1.2× 35 0.6× 24 0.4× 30 350
Emma J. West United Kingdom 10 189 1.5× 196 1.7× 123 1.1× 9 0.1× 12 0.2× 22 360
Subodh Kumar United States 10 76 0.6× 50 0.4× 358 3.3× 39 0.6× 8 0.1× 40 481
Udaya S. Rangaswamy United States 11 189 1.5× 40 0.4× 58 0.5× 28 0.4× 5 0.1× 19 321
E. Klein Sweden 11 104 0.8× 40 0.4× 93 0.8× 43 0.7× 15 0.3× 26 373
Christoph B. Geier Austria 9 57 0.5× 51 0.4× 37 0.3× 37 0.6× 22 0.4× 23 220
Emily Hopewell United States 8 172 1.4× 30 0.3× 112 1.0× 24 0.4× 8 0.1× 10 389
Sabrina Crivellaro Italy 12 88 0.7× 33 0.3× 257 2.3× 121 1.9× 72 1.2× 20 352

Countries citing papers authored by Tim Peterson

Since Specialization
Citations

This map shows the geographic impact of Tim Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Peterson more than expected).

Fields of papers citing papers by Tim Peterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Peterson. The network helps show where Tim Peterson may publish in the future.

Co-authorship network of co-authors of Tim Peterson

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Peterson. A scholar is included among the top collaborators of Tim Peterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Peterson. Tim Peterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Buege, Michael J., Esther Drill, Steven M. Horwitz, et al.. (2023). Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European Journal Of Haematology. 111(1). 96–102.
2.
Buege, Michael J., et al.. (2021). IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Clinical Lymphoma Myeloma & Leukemia. 21(12). 873–878. 1 indexed citations
3.
4.
Hultcrantz, Malin, Tim Peterson, Andriy Derkach, et al.. (2021). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood. 138(Supplement 1). 1644–1644. 7 indexed citations
5.
Buege, Michael J., et al.. (2020). Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy. 54(9). 879–898. 4 indexed citations
6.
Buege, Michael J., et al.. (2020). IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era. Blood. 136(Supplement 1). 10–10.
7.
Peterson, Tim, et al.. (2019). Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Annals of Pharmacotherapy. 54(6). 577–582. 20 indexed citations
8.
Mentz, Robert J., Adam D. DeVore, Gudaye Tasissa, et al.. (2019). Abstract 252: PredischaRge Initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. Circulation Cardiovascular Quality and Outcomes. 12(Suppl_1). 2 indexed citations
9.
Peterson, Tim, Neha Korde, Hani Hassoun, et al.. (2019). An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. Blood. 134(Supplement_1). 5554–5554.
10.
Hassoun, Hani, Larry W. Buie, Sean M. Devlin, et al.. (2019). VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. Blood. 134(Supplement_1). 1835–1835. 9 indexed citations
11.
Tang, Laura, et al.. (2018). Current and Investigational Agents Targeting the Phosphoinositide 3‐Kinase Pathway. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 38(10). 1058–1067. 14 indexed citations
12.
Pastores, Stephen M., Debra A. Goldman, David Shaz, et al.. (2018). Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer. 124(14). 3025–3036. 13 indexed citations
13.
King, Amber C., et al.. (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Annals of Pharmacotherapy. 51(5). 410–416. 32 indexed citations
14.
Peterson, Tim, Andrew Lin, Patrick Hilden, et al.. (2015). Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 1290–1290.
15.
Cockle, Julia, Karishma Rajani, Shane Zaidi, et al.. (2015). Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology. 18(4). 518–527. 57 indexed citations
16.
Bateman, Andrew, Kevin J. Harrington, Tim Kottke, et al.. (2002). Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.. PubMed. 62(22). 6566–78. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robin Mueller Breakdown of academic impact, for papers by Eva‐Maria König Breakdown of academic impact, for papers by N Tsuruoka Breakdown of academic impact, for papers by Emma J. West Breakdown of academic impact, for papers by Subodh Kumar Breakdown of academic impact, for papers by Udaya S. Rangaswamy Breakdown of academic impact, for papers by E. Klein Breakdown of academic impact, for papers by Christoph B. Geier Breakdown of academic impact, for papers by Emily Hopewell Breakdown of academic impact, for papers by Sabrina Crivellaro
Rankless by CCL
2026